Listed

Aytu Biopharma, Inc

AYTUNasdaqCIK 1385818HealthcareFiscal year ends Jun 30

Latest reported revenue, Q4 FY2026$16.1mRevenue, Q4 FY2026, three months to 2026-06-30$16.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-09-22, accession 0001437749-26-030908. Derived: 12-month figure less the 9-month figure.Report this figureThree months to Jun 30, 2026, from the 10-K filed Sep 22, 2026.

Latest quarter: Q4 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$16.1mRevenue, Q4 FY2026, three months to 2026-06-30$16.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-09-22, accession 0001437749-26-030908. Derived: 12-month figure less the 9-month figure.Report this figure+6.4% on a year earlier
  • Gross margin64.6%Gross margin, Q4 FY2026, three months to 2026-06-30. gross profit / revenueGross profit: $10.4m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-09-22, accession 0001437749-26-030908. Derived: 12-month figure less the 9-month figure.Revenue: $16.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-09-22, accession 0001437749-26-030908. Derived: 12-month figure less the 9-month figure.Report this figure−3.1 pts on a year earlier
  • Operating margin−4.8%Operating margin, Q4 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$777.0k. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-09-22, accession 0001437749-26-030908. Derived: 12-month figure less the 9-month figure.Revenue: $16.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-09-22, accession 0001437749-26-030908. Derived: 12-month figure less the 9-month figure.Report this figure+45.5 pts on a year earlier
  • Net margin−0.1%Net margin, Q4 FY2026, three months to 2026-06-30. net income / revenueNet income: −$15.0k. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-09-22, accession 0001437749-26-030908. Derived: 12-month figure less the 9-month figure.Revenue: $16.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-09-22, accession 0001437749-26-030908. Derived: 12-month figure less the 9-month figure.Report this figure+130.8 pts on a year earlier
  • Diluted EPSnot reported (Diluted EPS not reported)No year-earlier figure to compare
  • Free cash flow$4.4mFree cash flow, Q4 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $4.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-09-22, accession 0001437749-26-030908. Derived: 12-month figure less the 9-month figure.Capital expenditure: $12.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-09-22, accession 0001437749-26-030908. Derived: 12-month figure less the 9-month figure.Report this figure+57.7% on a year earlier

Last eight quarters

Full statements
Revenue$16.1mGross margin 64.6%
Diluted EPS−$0.53, Q3 FY2026
Free cash flow$4.4m, Q4 FY2026
Aytu Biopharma, Inc, key figures for the last eight quarters
Line itemUnitQ1 FY20252024-09-30Q2 FY20252024-12-31Q3 FY20252025-03-31Q4 FY20252025-06-30Q1 FY20262025-09-30Q2 FY20262025-12-31Q3 FY20262026-03-31Q4 FY20262026-06-30Shape over the periods
Revenue$m16.6Revenue, Q1 FY2025, three months to 2024-09-30$16.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-13, accession 0001437749-25-034825.Report this figure16.2Revenue, Q2 FY2025, three months to 2024-12-31$16.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-02-03, accession 0001437749-26-002804.Report this figure18.5Revenue, Q3 FY2025, three months to 2025-03-31$18.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-13, accession 0001437749-26-016721.Report this figure15.1Revenue, Q4 FY2025, three months to 2025-06-30$15.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-09-22, accession 0001437749-26-030908. Derived: 12-month figure less the 9-month figure.Report this figure13.9Revenue, Q1 FY2026, three months to 2025-09-30$13.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-13, accession 0001437749-25-034825.Report this figure15.2Revenue, Q2 FY2026, three months to 2025-12-31$15.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-02-03, accession 0001437749-26-002804.Report this figure12.4Revenue, Q3 FY2026, three months to 2026-03-31$12.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-13, accession 0001437749-26-016721.Report this figure16.1Revenue, Q4 FY2026, three months to 2026-06-30$16.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-09-22, accession 0001437749-26-030908. Derived: 12-month figure less the 9-month figure.Report this figure
Gross margin%72.3%Gross margin, Q1 FY2025, three months to 2024-09-30. gross profit / revenueGross profit: $12.0m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-11-13, accession 0001437749-25-034825.Revenue: $16.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-13, accession 0001437749-25-034825.Report this figure66.5%Gross margin, Q2 FY2025, three months to 2024-12-31. gross profit / revenueGross profit: $10.8m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-02-03, accession 0001437749-26-002804.Revenue: $16.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-02-03, accession 0001437749-26-002804.Report this figure69.4%Gross margin, Q3 FY2025, three months to 2025-03-31. gross profit / revenueGross profit: $12.8m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-13, accession 0001437749-26-016721.Revenue: $18.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-13, accession 0001437749-26-016721.Report this figure67.8%Gross margin, Q4 FY2025, three months to 2025-06-30. gross profit / revenueGross profit: $10.3m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-09-22, accession 0001437749-26-030908. Derived: 12-month figure less the 9-month figure.Revenue: $15.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-09-22, accession 0001437749-26-030908. Derived: 12-month figure less the 9-month figure.Report this figure66.1%Gross margin, Q1 FY2026, three months to 2025-09-30. gross profit / revenueGross profit: $9.2m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2025-11-13, accession 0001437749-25-034825.Revenue: $13.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-13, accession 0001437749-25-034825.Report this figure63.5%Gross margin, Q2 FY2026, three months to 2025-12-31. gross profit / revenueGross profit: $9.6m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-02-03, accession 0001437749-26-002804.Revenue: $15.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-02-03, accession 0001437749-26-002804.Report this figure61.2%Gross margin, Q3 FY2026, three months to 2026-03-31. gross profit / revenueGross profit: $7.6m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-13, accession 0001437749-26-016721.Revenue: $12.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-13, accession 0001437749-26-016721.Report this figure64.6%Gross margin, Q4 FY2026, three months to 2026-06-30. gross profit / revenueGross profit: $10.4m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-09-22, accession 0001437749-26-030908. Derived: 12-month figure less the 9-month figure.Revenue: $16.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-09-22, accession 0001437749-26-030908. Derived: 12-month figure less the 9-month figure.Report this figure
Operating margin%(5.6%)Operating margin, Q1 FY2025, three months to 2024-09-30. operating income / revenueOperating income: −$930.0k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-13, accession 0001437749-25-034825.Revenue: $16.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-13, accession 0001437749-25-034825.Report this figure(10.4%)Operating margin, Q2 FY2025, three months to 2024-12-31. operating income / revenueOperating income: −$1.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-02-03, accession 0001437749-26-002804.Revenue: $16.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-02-03, accession 0001437749-26-002804.Report this figure13.1%Operating margin, Q3 FY2025, three months to 2025-03-31. operating income / revenueOperating income: $2.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-13, accession 0001437749-26-016721.Revenue: $18.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-13, accession 0001437749-26-016721.Report this figure(50.4%)Operating margin, Q4 FY2025, three months to 2025-06-30. operating income / revenueOperating income: −$7.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-09-22, accession 0001437749-26-030908. Derived: 12-month figure less the 9-month figure.Revenue: $15.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-09-22, accession 0001437749-26-030908. Derived: 12-month figure less the 9-month figure.Report this figure(10.8%)Operating margin, Q1 FY2026, three months to 2025-09-30. operating income / revenueOperating income: −$1.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-13, accession 0001437749-25-034825.Revenue: $13.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-13, accession 0001437749-25-034825.Report this figure(13.0%)Operating margin, Q2 FY2026, three months to 2025-12-31. operating income / revenueOperating income: −$2.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-02-03, accession 0001437749-26-002804.Revenue: $15.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-02-03, accession 0001437749-26-002804.Report this figure(32.7%)Operating margin, Q3 FY2026, three months to 2026-03-31. operating income / revenueOperating income: −$4.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-13, accession 0001437749-26-016721.Revenue: $12.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-13, accession 0001437749-26-016721.Report this figure(4.8%)Operating margin, Q4 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$777.0k. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-09-22, accession 0001437749-26-030908. Derived: 12-month figure less the 9-month figure.Revenue: $16.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-09-22, accession 0001437749-26-030908. Derived: 12-month figure less the 9-month figure.Report this figure
Net margin%8.9%Net margin, Q1 FY2025, three months to 2024-09-30. net income / revenueNet income: $1.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-13, accession 0001437749-26-016721.Revenue: $16.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-13, accession 0001437749-25-034825.Report this figure4.9%Net margin, Q2 FY2025, three months to 2024-12-31. net income / revenueNet income: $788.0k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-13, accession 0001437749-26-016721.Revenue: $16.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-02-03, accession 0001437749-26-002804.Report this figure21.6%Net margin, Q3 FY2025, three months to 2025-03-31. net income / revenueNet income: $4.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-13, accession 0001437749-26-016721.Revenue: $18.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-13, accession 0001437749-26-016721.Report this figure(130.9%)Net margin, Q4 FY2025, three months to 2025-06-30. net income / revenueNet income: −$19.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-09-22, accession 0001437749-26-030908. Derived: 12-month figure less the 9-month figure.Revenue: $15.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-09-22, accession 0001437749-26-030908. Derived: 12-month figure less the 9-month figure.Report this figure14.1%Net margin, Q1 FY2026, three months to 2025-09-30. net income / revenueNet income: $2.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-13, accession 0001437749-26-016721.Revenue: $13.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-13, accession 0001437749-25-034825.Report this figure(69.8%)Net margin, Q2 FY2026, three months to 2025-12-31. net income / revenueNet income: −$10.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-13, accession 0001437749-26-016721.Revenue: $15.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-02-03, accession 0001437749-26-002804.Report this figure(45.3%)Net margin, Q3 FY2026, three months to 2026-03-31. net income / revenueNet income: −$5.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-13, accession 0001437749-26-016721.Revenue: $12.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-13, accession 0001437749-26-016721.Report this figure(0.1%)Net margin, Q4 FY2026, three months to 2026-06-30. net income / revenueNet income: −$15.0k. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-09-22, accession 0001437749-26-030908. Derived: 12-month figure less the 9-month figure.Revenue: $16.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-09-22, accession 0001437749-26-030908. Derived: 12-month figure less the 9-month figure.Report this figure
Diluted EPS$ per share(0.15)Diluted EPS, Q1 FY2025, three months to 2024-09-30−$0.15 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001437749-25-034825.Report this figure(0.26)Diluted EPS, Q2 FY2025, three months to 2024-12-31−$0.26 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-02-03, accession 0001437749-26-002804.Report this figure0.21Diluted EPS, Q3 FY2025, three months to 2025-03-31$0.21 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-13, accession 0001437749-26-016721.Report this figurenot reported (Diluted EPS not reported)(0.08)Diluted EPS, Q1 FY2026, three months to 2025-09-30−$0.08 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001437749-25-034825.Report this figure(1.05)Diluted EPS, Q2 FY2026, three months to 2025-12-31−$1.05 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-02-03, accession 0001437749-26-002804.Report this figure(0.53)Diluted EPS, Q3 FY2026, three months to 2026-03-31−$0.53 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-13, accession 0001437749-26-016721.Report this figurenot reported (Diluted EPS not reported)
Free cash flow$m(1.3)Free cash flow, Q1 FY2025, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: −$1.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-13, accession 0001437749-25-034825.Capital expenditure: $136.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-13, accession 0001437749-25-034825.Report this figure2.9Free cash flow, Q2 FY2025, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $2.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-02-03, accession 0001437749-26-002804. Derived: 6-month figure less the 3-month figure.Capital expenditure: $6.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-02-03, accession 0001437749-26-002804. Derived: 6-month figure less the 3-month figure.Report this figure(6.5)Free cash flow, Q3 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: −$6.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-13, accession 0001437749-26-016721. Derived: 9-month figure less the 6-month figure.Capital expenditure: $69.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-13, accession 0001437749-26-016721. Derived: 9-month figure less the 6-month figure.Report this figure2.8Free cash flow, Q4 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: $2.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-09-22, accession 0001437749-26-030908. Derived: 12-month figure less the 9-month figure.Capital expenditure: $17.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-09-22, accession 0001437749-26-030908. Derived: 12-month figure less the 9-month figure.Report this figure(0.6)Free cash flow, Q1 FY2026, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: −$618.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-13, accession 0001437749-25-034825.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-13, accession 0001437749-25-034825.Report this figure3.7Free cash flow, Q2 FY2026, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $3.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-02-03, accession 0001437749-26-002804. Derived: 6-month figure less the 3-month figure.Capital expenditure: $17.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-02-03, accession 0001437749-26-002804. Derived: 6-month figure less the 3-month figure.Report this figure(4.2)Free cash flow, Q3 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: −$4.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-13, accession 0001437749-26-016721. Derived: 9-month figure less the 6-month figure.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-13, accession 0001437749-26-016721. Derived: 9-month figure less the 6-month figure.Report this figure4.4Free cash flow, Q4 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $4.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-09-22, accession 0001437749-26-030908. Derived: 12-month figure less the 9-month figure.Capital expenditure: $12.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-09-22, accession 0001437749-26-030908. Derived: 12-month figure less the 9-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$57.6mGross margin 64.0%
Diluted EPS−$5.11, FY2023
Free cash flow$3.3m, FY2026
Aytu Biopharma, Inc, key figures for the last five fiscal years
Line itemUnitFY20222022-06-30FY20232023-06-30FY20242024-06-30FY20252025-06-30FY20262026-06-30Shape over the periods
Revenue$m96.7Revenue, FY2022, twelve months to 2022-06-30$96.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-10-12, accession 0001558370-23-016393.Report this figure107Revenue, FY2023, twelve months to 2023-06-30$107.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-09-26, accession 0001437749-24-030062.Report this figure65.2Revenue, FY2024, twelve months to 2024-06-30$65.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-09-23, accession 0001437749-25-029723.Report this figure66.4Revenue, FY2025, twelve months to 2025-06-30$66.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-09-22, accession 0001437749-26-030908.Report this figure57.6Revenue, FY2026, twelve months to 2026-06-30$57.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-09-22, accession 0001437749-26-030908.Report this figure
Gross margin%54.1%Gross margin, FY2022, twelve months to 2022-06-30. gross profit / revenueGross profit: $52.3m. XBRL concept us-gaap:GrossProfit. 10-K filed 2023-10-12, accession 0001558370-23-016393.Revenue: $96.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-10-12, accession 0001558370-23-016393.Report this figure62.0%Gross margin, FY2023, twelve months to 2023-06-30. gross profit / revenueGross profit: $66.6m. XBRL concept us-gaap:GrossProfit. 10-K filed 2024-09-26, accession 0001437749-24-030062.Revenue: $107.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-09-26, accession 0001437749-24-030062.Report this figure75.3%Gross margin, FY2024, twelve months to 2024-06-30. gross profit / revenueGross profit: $49.1m. XBRL concept us-gaap:GrossProfit. 10-K filed 2025-09-23, accession 0001437749-25-029723.Revenue: $65.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-09-23, accession 0001437749-25-029723.Report this figure69.0%Gross margin, FY2025, twelve months to 2025-06-30. gross profit / revenueGross profit: $45.8m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-09-22, accession 0001437749-26-030908.Revenue: $66.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-09-22, accession 0001437749-26-030908.Report this figure64.0%Gross margin, FY2026, twelve months to 2026-06-30. gross profit / revenueGross profit: $36.8m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-09-22, accession 0001437749-26-030908.Revenue: $57.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-09-22, accession 0001437749-26-030908.Report this figure
Operating margin%(113.7%)Operating margin, FY2022, twelve months to 2022-06-30. operating income / revenueOperating income: −$109.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2023-10-12, accession 0001558370-23-016393.Revenue: $96.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-10-12, accession 0001558370-23-016393.Report this figure(15.9%)Operating margin, FY2023, twelve months to 2023-06-30. operating income / revenueOperating income: −$17.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-09-26, accession 0001437749-24-030062.Revenue: $107.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-09-26, accession 0001437749-24-030062.Report this figure(2.4%)Operating margin, FY2024, twelve months to 2024-06-30. operating income / revenueOperating income: −$1.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-09-23, accession 0001437749-25-029723.Revenue: $65.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-09-23, accession 0001437749-25-029723.Report this figure(11.8%)Operating margin, FY2025, twelve months to 2025-06-30. operating income / revenueOperating income: −$7.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-09-22, accession 0001437749-26-030908.Revenue: $66.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-09-22, accession 0001437749-26-030908.Report this figure(14.4%)Operating margin, FY2026, twelve months to 2026-06-30. operating income / revenueOperating income: −$8.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-09-22, accession 0001437749-26-030908.Revenue: $57.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-09-22, accession 0001437749-26-030908.Report this figure
Net margin%(112.5%)Net margin, FY2022, twelve months to 2022-06-30. net income / revenueNet income: −$108.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2023-10-12, accession 0001558370-23-016393.Revenue: $96.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-10-12, accession 0001558370-23-016393.Report this figure(15.9%)Net margin, FY2023, twelve months to 2023-06-30. net income / revenueNet income: −$17.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-09-26, accession 0001437749-24-030062.Revenue: $107.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-09-26, accession 0001437749-24-030062.Report this figure(24.3%)Net margin, FY2024, twelve months to 2024-06-30. net income / revenueNet income: −$15.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-09-23, accession 0001437749-25-029723.Revenue: $65.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-09-23, accession 0001437749-25-029723.Report this figure(20.4%)Net margin, FY2025, twelve months to 2025-06-30. net income / revenueNet income: −$13.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-09-22, accession 0001437749-26-030908.Revenue: $66.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-09-22, accession 0001437749-26-030908.Report this figure(24.8%)Net margin, FY2026, twelve months to 2026-06-30. net income / revenueNet income: −$14.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-09-22, accession 0001437749-26-030908.Revenue: $57.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-09-22, accession 0001437749-26-030908.Report this figure
Diluted EPS$ per share(74.01)Diluted EPS, FY2022, twelve months to 2022-06-30−$74.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2023-10-12, accession 0001558370-23-016393.Report this figure(5.11)Diluted EPS, FY2023, twelve months to 2023-06-30−$5.11 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2023-10-12, accession 0001558370-23-016393.Report this figurenot reported (Diluted EPS not reported)not reported (Diluted EPS not reported)not reported (Diluted EPS not reported)
Free cash flow$m(28.8)Free cash flow, FY2022, twelve months to 2022-06-30. operating cash flow − capital expenditureOperating cash flow: −$28.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2023-10-12, accession 0001558370-23-016393.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquireProductiveAssets. 10-K filed 2022-09-27, accession 0001558370-22-014652.Report this figurenot reported (Capital expenditure not reported)(1.7)Free cash flow, FY2024, twelve months to 2024-06-30. operating cash flow − capital expenditureOperating cash flow: −$1.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-09-23, accession 0001437749-25-029723.Capital expenditure: $329.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-09-23, accession 0001437749-25-029723.Report this figure(2.2)Free cash flow, FY2025, twelve months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: −$1.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-09-22, accession 0001437749-26-030908.Capital expenditure: $228.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-09-22, accession 0001437749-26-030908.Report this figure3.3Free cash flow, FY2026, twelve months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $3.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-09-22, accession 0001437749-26-030908.Capital expenditure: $29.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-09-22, accession 0001437749-26-030908.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

Aytu Biopharma, Inc, open-market insider transactions
DateInsiderTransactionSharesReported priceValueFiling
2020-04-15Cerecor Inc.10% owner Sale92,777$1.5531$144.1kForm 4

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Aytu Biopharma, Inc
FundQuarter endedReported valueSharesPut or callChange on the quarter before
Nantahala Capital Management, LLC2026-06-30$2.3m1,086,812Unchanged
Nantahala Capital Management, LLC2026-06-30$2.3m1,086,812Unchanged
Stonepine Capital Management, LLC2026-06-30$2.0m912,921Added+120,632
AWM Investment Company, Inc.2026-06-30$1.3m619,574Unchanged
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$561.5k261,146Unchanged
CROWN ADVISORS MANAGEMENT, INC.2026-06-30$430.0k200,000Added+55,000
DIADEMA PARTNERS LP2026-06-30$319.4k148,546Reduced−204,531
TWO SIGMA INVESTMENTS, LP2026-06-30$226.5k105,326Reduced−16,647
RENAISSANCE TECHNOLOGIES LLC2026-06-30$225.4k104,823Added+11,100
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$201.4k93,647Added+1,011

Recent filings

All 886 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Aytu Biopharma, Inc, recent filings
FiledFormWhat it isAccession number
2026-10-2216:30 ETDEF 14AProxy statementPeriod 2026-12-100001437749-26-033276
2026-09-2216:14 ET10-KAnnual reportPeriod 2026-06-300001437749-26-030908
2026-09-2216:05 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001437749-26-030900
2026-06-2516:31 ET8-K1.02 Termination of a material agreement0001437749-26-021707
2026-05-1316:08 ET10-QQuarterly reportPeriod 2026-03-310001437749-26-016721
2026-05-1316:05 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001437749-26-016717
2026-04-0216:08 ET8-K1.01 Entry into a material agreement; 2.02 Results of operations; 3.02 Unregistered sale of equity; 3.03 Change to security holders’ rights; 9.01 Financial statements and exhibits0001437749-26-011116
2026-02-0316:08 ET10-QQuarterly reportPeriod 2025-12-310001437749-26-002804
2026-02-0316:05 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001437749-26-002799
2026-01-2016:05 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001437749-26-001543

Latest annual report

Form 10-K for the fiscal year ended Jun 30, 2026Filed Sep 22, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q1 FY2027, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
1385818
Tickers
AYTU
Exchange
Nasdaq
SIC code
2834 Pharmaceutical Preparations
Sector
Healthcare
Fiscal year ends
Jun 30
Incorporated in
DE
Filer category
Non-accelerated filer<br>Smaller reporting company
Former names
AYTU BIOSCIENCE, INC (to 2021-03-22); Rosewind CORP (to 2015-06-08)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 16:32 ET. Listed shows no prices and gives no investment advice.